Back to Search
Start Over
Immunomodulatory therapy for sepsis: An update
- Source :
- Expert Review of Anti-Infective Therapy
- Publication Year :
- 2011
-
Abstract
- Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis. © 2011 Expert Reviews Ltd. 9 11 1013 1033
- Subjects :
- Simvastatin
Hydrocortisone
3 (2
Apoptosis
Review
Adaptive Immunity
Signal transduction
Acute kidney failure
Mice
Endotoxin
Bacterial infections
Septic shock
Continuous hemofiltration
4 dimethoxybenzylidene)anabaseine
Protein c
Inter alpha inhibitor protein
Hemoadsorption device
Abdominal infection
Coupled plasma filtration adsorption
Thymosin alpha1
Immunologic factors
Blood clotting disorder
Protein antibody
Human
Anticoagulant agent
Microbiology (medical)
Drug megadose
Multiple Organ Failure
Diet supplementation
Microbiology
Proinflammatory cytokine
Immunomodulatory strategies
Hydroxymethylglutaryl coenzyme a reductase inhibitor
Anti-bacterial agents
Antiinflammatory agent
Sepsis
Talactoferrin
Oxiris
Immunologic Factors
Humans
Device
Hospital infection
Immunoparalysis
Renal replacement therapy
Immunity
Ulinastatin
medicine.disease
Immunity, Innate
Endotoxemia
Lactoferrin
Immunology
Disseminated intravascular clotting
Bacterial infection
Immunostimulation
Inhibitor protein
Unclassified drug
Ventilator associated pneumonia
Anti-Inflammatory Agents
Cytofab
High mobility group b1 protein antibody
Liver injury
Respiratory failure
Acute lung injury
Innate
Nephrotoxicity
Adenosine a2a receptor agonist
Anti-inflammatory agents
Clinical Trials as Topic
Superantigen
Cholinergic stimulation
Antibiotic agent
Ceftriaxone
Bacterial Infections
Anti-Bacterial Agents
Complement activation
Didemethoxycurcumin
Infectious Diseases
Gram-negative bacteria
Kidney injury
Advanced glycation end product receptor
Animal studies
Complement inhibitor
medicine.symptom
Eritoran
medicine.drug
Polymyxin b
Adaptive immunity
Inflammation
Protein targeting
Pathophysiology
Antibodies
Immunomodulation
Rosiglitazone
Clinical trials as topic
Anticoagulation
Immune system
Virology
Clarithromycin
Gram-Negative Bacteria
medicine
Neurotoxicity
Kidney dysfunction
Animals
Placebo
business.industry
Intermethod comparison
Incyclinide
Renal tubule assist device
Nonhuman
Multiple organ failure
Resatorvid
Community acquired pneumonia
Adenosine a2a receptor
business
Unindexed drug
Protein C
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Expert Review of Anti-Infective Therapy
- Accession number :
- edsair.doi.dedup.....048b8ac795c183c749baf098b496a08b